AstraZeneca PLC - American Depositary Shares (AZN)

Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.

Full results from the positive Phase III WAYPOINT trial showed AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) significantly reduced nasal polyp severity, the need for subsequent surgery, and systemic corticosteroid use in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) compared to placebo.1,2 These data were published in the New England Journal of Medicine and presented today as a late-breaking oral presentation at the American Academy of Allergy Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress in San Diego, CA.1,2

IonQ CEO Niccolo De Masi is confident that quantum computing will soon be the third leg of computing. With major partnerships and predicted GAAP revenue, IonQ is poised to be a leader in the industry.

Snowflake unveiled its deeper partnership with Microsoft Corp during its earnings call and introduced its new AI agent Cortex.

AstraZeneca's SERENA-6 trial shows camizestrant plus a CDK4/6 inhibitor improves progression-free survival in HR-positive, HER2-negative breast cancer.

The top nine American companies by market cap are all worth more than a trillion dollars.

Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) demonstrated a highly statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS). The trial evaluated switching to the camizestrant combination versus continuing standard-of-care treatment with an aromatase inhibitor (AI) (anastrozole or letrozole) in combination with a CDK4/6 inhibitor in the 1st-line treatment of patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumors have an emergent ESR1 mutation.

Elon Musk and Neurolinks has been loud about the singularity—AI surpassing human intelligence. But has curiosity has lost its oomph?

A fundamental analysis of (NASDAQAZN): Is ASTRAZENECA PLC-SPONS ADR NASDAQ:AZNNASDAQAZN)

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQAZN) and reminds investors of the Feb. 21, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its CD46-targeting ADC and PET imaging agent.

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQAZN) between February 23, 2022 and December 17, 2024, both dates inclusive (the “Class Period”), of the February 21, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.

European fund managers are bullish on stocks, with 3 top ETFs to consider: SPDR EURO STOXX 50 (FEZ), Vanguard FTSE Europe (VGK), Xtrackers MSCI EAFE Hedged Equity (DBEF)

Soros Fund Management made bullish bets on Alphabet and small-cap stocks while reducing exposure to SPY and Chinese tech in Q4.

The Law Offices of Frank R. Cruz reminds investors of the upcoming February 21, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQAZN) securities between February 23, 2022 and December 17, 2024, inclusive (the “Class Period”).

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In AstraZenecaTo Contact Him Directly To Discuss Their Options

AstraZeneca's Imfinzi perioperative regimen improved survival outcomes in muscle-invasive bladder cancer, with FDA Priority Review expected in Q2 2025.

Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab), administered perioperatively in combination with neoadjuvant chemotherapy, demonstrated improvements in event-free survival (EFS) and overall survival (OS) versus neoadjuvant chemotherapy with radical cystectomy alone in patients with or without a pathologic complete response (pCR) in muscle-invasive bladder cancer (MIBC). Patients were treated with four cycles of IMFINZI in combination with neoadjuvant chemotherapy before radical cystectomy (surgery to remove the bladder) followed by eight cycles of IMFINZI monotherapy.

Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target.